contractpharmaMay 05, 2017
Tag: Regeneron , Financial Report
1Q Revenues: $1.3 billion (+10%)
1Q Earnings: $249 million
Comments: Global EYLEA sales were up 12% in the quarter to $1.3 billion. Sales of EYLEA in the U.S. increased 9% to $854 million. Bayer commercializes EYLEA outside the U.S. Global sales of Praluent were $36 million, compared to $13 million in 1Q16. R&D expenses were $507 million in the quarter compared to $470 million in 1Q16. In the quarter, the company received U.S. FDA approval for Dupixent, a therapy for moderate-to-severe atopic dermatitis.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: